CureC9 and BrainXell Collaborate to Propel ALS and FTD Research Efforts
In a significant development for ALS (Amyotrophic Lateral Sclerosis) and FTD (Frontotemporal Dementia) research, CureC9 is joining forces with BrainXell, Inc. Together, they aim to transform patient-driven innovation into tangible scientific advancements. This collaboration seeks to provide high-quality, patient-derived human induced pluripotent stem cell (iPSC) models, paving the way for groundbreaking research in these devastating neurodegenerative diseases.
CureC9, a pioneering initiative focused on C9orf72-associated conditions, has dedicated itself to accelerating treatments that target the underlying causes of ALS and FTD. The partnership with BrainXell will significantly enhance the accessibility of essential biological resources for researchers globally. By creating a comprehensive biorepository, they hope to expedite the scientific quest for effective therapies, tackling the challenges faced by patients and their families.
At the heart of this collaboration is Yentli Soto Albrecht, PhD, Co-Founder of CureC9 and a dedicated MD-PhD candidate at the University of Pennsylvania. Soto Albrecht, along with her late father's contribution of skin cells, is pivotal in establishing the first patient-derived cell lines within the C9orf72 biorepository. These skin cells will be transformed into iPSCs, which can then differentiate into various central nervous system cell types that are crucial for understanding ALS and FTD.
"BrainXell was among the early partners in my mission to expedite a cure for these diseases within my lifetime," stated Soto Albrecht. She further added that this partnership aims to break down barriers, allowing researchers to focus more on their work and less on hurdles that slow down progress. This type of patient engagement is a model for future collaborative efforts, where individuals and families affected by C9orf72-associated diseases will be invited to contribute biological samples to broaden the biorepository. Importantly, part of the proceeds from the initiative will support CureC9’s ongoing mission to empower the patient community and further accelerate research endeavors.
The partnership offers a unique resource for both academic and industrial researchers, facilitating a deeper understanding of disease biology and evaluating new therapeutic strategies. Enhanced access to these standardized, commercially available models will ultimately expedite the search for effective treatments for ALS and FTD.
CureC9 strives to reduce barriers in research, enhance access to resources relevant to these diseases, and foster collaboration among patients, scientists, healthcare professionals, nonprofits, and industry stakeholders. This revolutionary partnership is set to reshape the landscape of research on ALS and FTD, thereby improving the lives of countless patients and their families.
For further information about CureC9 and its initiatives, please visit curec9.com, where visitors can explore the mission and the ongoing efforts to combat these challenging neurological diseases. This collaboration signifies a step forward in the quest for innovation and care in the realm of neurodegenerative conditions, ensuring that the voices of patients remain at the forefront of research progress.
CureC9, a pioneering initiative focused on C9orf72-associated conditions, has dedicated itself to accelerating treatments that target the underlying causes of ALS and FTD. The partnership with BrainXell will significantly enhance the accessibility of essential biological resources for researchers globally. By creating a comprehensive biorepository, they hope to expedite the scientific quest for effective therapies, tackling the challenges faced by patients and their families.
At the heart of this collaboration is Yentli Soto Albrecht, PhD, Co-Founder of CureC9 and a dedicated MD-PhD candidate at the University of Pennsylvania. Soto Albrecht, along with her late father's contribution of skin cells, is pivotal in establishing the first patient-derived cell lines within the C9orf72 biorepository. These skin cells will be transformed into iPSCs, which can then differentiate into various central nervous system cell types that are crucial for understanding ALS and FTD.
"BrainXell was among the early partners in my mission to expedite a cure for these diseases within my lifetime," stated Soto Albrecht. She further added that this partnership aims to break down barriers, allowing researchers to focus more on their work and less on hurdles that slow down progress. This type of patient engagement is a model for future collaborative efforts, where individuals and families affected by C9orf72-associated diseases will be invited to contribute biological samples to broaden the biorepository. Importantly, part of the proceeds from the initiative will support CureC9’s ongoing mission to empower the patient community and further accelerate research endeavors.
The partnership offers a unique resource for both academic and industrial researchers, facilitating a deeper understanding of disease biology and evaluating new therapeutic strategies. Enhanced access to these standardized, commercially available models will ultimately expedite the search for effective treatments for ALS and FTD.
CureC9 strives to reduce barriers in research, enhance access to resources relevant to these diseases, and foster collaboration among patients, scientists, healthcare professionals, nonprofits, and industry stakeholders. This revolutionary partnership is set to reshape the landscape of research on ALS and FTD, thereby improving the lives of countless patients and their families.
For further information about CureC9 and its initiatives, please visit curec9.com, where visitors can explore the mission and the ongoing efforts to combat these challenging neurological diseases. This collaboration signifies a step forward in the quest for innovation and care in the realm of neurodegenerative conditions, ensuring that the voices of patients remain at the forefront of research progress.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.